Abstract: SUN Yong-xin*, FANG Xu, CUI Bing-nan, HUANG Qiong, JIANG Gui-xian, DAI Yuan-yuan, KONG Qian, DU Xiu-lan, ZHU Guang-yi, ZHANG He-ye． *Department of Dermatology, Tanggangzi Hospital of Anshan City, Anshan 114048, Liaoning, China Corresponding author: FANG Xu, Email: xu_f50@163.com 【Abstract】 Objective To assess the efficacy and safety of calcipotriol betamethasone ointment combined with narrow band-ultraviolet B （NB-UVB） for the treatment of plaque-type psoriasis. Methods A randomized, single-blind, parallel-controlled, multi-center clinical trial was conducted. Totally, 108 patients with plaque-type psoriasis were randomly divided into the experiment group （treated with NB-UVB plus topical calcipotriol betamethasone ointment once daily in the evening） and control group （treated with NB-UVB only）. The treatment lasted four weeks. The safety and efficacy were evaluated at the baseline, as well as two and four weeks after the beginning of treatment. Patients were scheduled for follow-up on week 1, 2 and 4 after the end of treatment. Results The response rate was 15.09% in the experiment group and 2.04% in the control group after two-week treatment （P < 0.01）, 77.36% in the experiment group and 26.53% in the control group at the end of treatment （P < 0.01）. Psoriasis area and severity index （PASI） score was similar between the two groups at the baseline, but significantly different from week 2 to week 8 after the beginning of treatment （all P < 0.01）. Adverse reaction was observed in none of these patients, except for one patient in the control group who developed painful erythema in non-lesional sites of both legs. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Calcipotriol betamethasone ointment combined with NB-UVB is a safe and effective treatment choice for plaque-type psoriasis with rapid onset of action.

Key words: Randomized controlled trials